GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Price-to-Funds-From-Operations

Biosyent (TSXV:RX) Price-to-Funds-From-Operations : (As of Mar. 30, 2025)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Biosyent Business Description

Industry
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Peter Douglas Lockhard Director
Blair Driscoll 10% Security Holder
Merrilyn Joy Driscoll 10% Security Holder
Sean Driscoll 10% Security Holder
Fax Capital Corp. 10% Security Holder
Fax Investments Inc. 10% Security Holder
Federated Capital Corp. 10% Security Holder
Seyed Ahmad Ashrafi Director
Robert Joseph March Senior Officer
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Joost Van Der Mark Senior Officer
Sara Elford Director
Alfred D'souza Director